Cargando…
Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck
SIMPLE SUMMARY: Squamous cell carcinoma of the head and neck (SCCHN) is a debilitating disease that affects hundreds of thousands of individuals worldwide and has a high mortality rate. Mainstay treatment largely consists of surgery, radiation, and chemotherapy which has been met with significant mo...
Autores principales: | Patel, Bhamini, Saba, Nabil F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306284/ https://www.ncbi.nlm.nih.gov/pubmed/34298761 http://dx.doi.org/10.3390/cancers13143545 |
Ejemplares similares
-
The Current Role of Salvage Surgery in Recurrent Head and Neck Squamous Cell Carcinoma
por: Hamoir, Marc, et al.
Publicado: (2018) -
Immunotherapy of Head and Neck Cancer: Current and Future Considerations
por: Rapidis, Alexander D., et al.
Publicado: (2009) -
EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
por: Kono, Scott A., et al.
Publicado: (2012) -
Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer
por: Baba, Yuh, et al.
Publicado: (2012) -
Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021)